Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country.

ABSTRACT:

Objective

To report a modelling study using local health care costs and epidemiological inputs from a population-based program to access the cost-effectiveness of adopting hrHPV test.

Methods

A cost-effectiveness analysis based on a microsimulation dynamic Markov model. Data and costs were based on data from the local setting and literature review. The setting was Indaiatuba, Brazil, that has adopted the hrHPV test in place of cytology since 2017. After calibrating the model, one million women were simulated in hypothetical cohorts. Three strategies were tested: cytology to women aged 25 to 64 every three years; hrHPV test to women 25-64 every five years; cytology to women 25-29 years every three years and hrHPV test to women 30-64 every five years (hybrid strategy). Outcome

SUBMITTER: Vale DB 

PROVIDER: S-EPMC8121350 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature